Press Release June 29, 2021European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma 0 0 Share
Company Ticker News June 27, 2021Week 26 MDA Breakout Stocks - July 2021: Short-Term Picks To Give You An Edge 0 0 Share
Company Ticker News June 26, 2021Forget Dogecoin: These Dogs of the Dow Are More Likely to Make You Rich 0 0 Share
Company Ticker News June 26, 2021Merck Desperate To Get Back In Coronavirus Race, With A Pill 0 0 Share
Press Release June 24, 2021LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer 0 0 Share
Company Ticker News June 23, 2021The 5 Poor Performing Dow Stocks in Warren Buffett's Portfolio 0 0 Share
Press Release June 22, 2021Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer 0 0 Share
Company Ticker News June 22, 2021Does The Valuation Gap Between Merck Stock And Zoetis Make Sense? 0 0 Share
Company Ticker News June 21, 2021Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack 0 0 Share
